Objective: Our aim was to estimate prevalence of metabolic syndrome (MS), obesity and comorbidities in a cohort of 120 children (3-18 years) with biopsy-proven non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) and to evaluate correlations between clinical or biochemical variables and liver histology. Research methods and procedures: MS was diagnosed according to the adapted National Cholesterol Education Program criteria. Homeostatic model assessment of insulin resistance (HOMA-IR), quantitative insulin-sensitivity check index (QUICKI); and ISI composite, insulin secretion (insulin response at 30 min after a glucose load; HOMA-b cell; insulinogenic index) were all estimated. BMI z-score and total body fat (dual-energy X-ray absorptiometry) were evaluated as indexes of obesity. Results: MS was diagnosed in 66% of children. About 92% had weight above the 85th percentile, of which 42% were obese with weight above 97th percentile. Prevalence of hypertriglyceridaemia was 63%, low HDL cholesterol 45%, hypertension 40% and impaired glucose tolerance 10%. Levels of aminotransferases were higher as the number of comorbidities increased, the highest values being found in subjects with MS (Pp0.05). Prevalence of a grade of steatosis X2 (P ¼ 0.05) and fibrosis (Pp0.01) was higher in subjects with MS. Histology was associated significantly with higher values of a number of clinical and biochemical parameters (steatosis X2 with BMI z-score (P ¼ 0.04), fasting insulin (P ¼ 0.02), HOMA-IR (P ¼ 0.03), b-cell secretion (P ¼ 0.04); necroinflammation with BMI z-score (P ¼ 0.007), glucose (Pp0.0001), cholesterol (Pp0.04) and white blood cells (P ¼ 0.025); fibrosis with body weight (P ¼ 0.05), BMI z-score (P ¼ 0.03), cholesterol (P ¼ 0.05), triglycerides (P ¼ 0.05), fasting insulin (Pp0.0001) and mean values of the hormone at the OGTT (P ¼ 0.03), HOMA-IR (Pp0.0001)). Conclusion: Presence of MS or clinical and biochemical variables associated with the syndrome seems to be strictly related to histological features of NASH in paediatric fatty liver disease. Thus, routinely liver biopsy should be encouraged in these children.
Introduction
In westernised countries, prevalence of paediatric obesity and comorbidities, which all cluster together in the metabolic syndrome (MS), 1 are going to reach epidemic proportions in the next decades. Comorbidities include impairment of glucose and insulin metabolism, (exhaustion of b-cell function, reduced systemic and peripheral insulin sensitivity), dyslipidaemia and hypertension. In the past decade, nonalcoholic fatty liver disease (NAFLD) has become a common report in obese or overweight subjects. 2 The disease may be regarded as feature of MS. 3 NAFLD may present as a spectrum of disease: from asymptomatic steatosis with elevated or normal aminotransferases to steatohepatitis (non-alcoholic steatohepatitis (NASH)), cirrhosis with complications of liver function to hepatocellular carcinoma. 2 NASH may be suspected if there is two-to threefold increased in aminotransferases levels and ultrasound liver brightness. However, definite diagnosis requires liver biopsy. 2 A number of studies have shown how components of MS may contribute to alanine aminotransferase (ALT) activity, [4] [5] [6] severe liver steatosis, 7, 8 NASH activity, 8, 9 fibrosis 8 or isolated portal fibrosis 10 in adults with NAFLD/NASH.
In childhood, NAFLD may develop very early in pre-school age. In Italy, diagnosis of NAFLD may be suspected in onefourth of obese children. 11 Conversely, obesity occurs in 40% of children with biopsy-proven NAFLD/NASH, 12, 13 overweight in 50%, insulin resistance (IR) in 62%, and 2% patients have type 2 diabetes mellitus (T2DM). 13 Obesity and IR seem to be strongly associated with increased risk of fibrosis and steatohepatitis. 13 In the present study, we aim to estimate prevalence of MS, obesity, clinical and biochemical features of metabolic impairment in the largest cohort of biopsy-proven NAFLD children hitherto described in the literature, and to investigate any relation of metabolic variables to liver histology.
Materials and methods

Patients
One hundred and twenty consecutive biopsy-proven NAFLD children (3-18 years) were enrolled from January 2003 to September 2006. Inclusion criteria were persistently elevated serum aminotransferases and/or fluctuating between normal and elevated levels, with two elevated measurements during the past 6 months before enrolment; diffusely echogenic liver imaging suggestive of fatty liver infiltration, exclusion of hepatic virus infections, no alcohol consumption, no history of parenteral nutrition, and no use of drugs able to induce steatosis. Known liver diseases were ruled out by appropriate test as described previously. 12 The study protocol was conformed to the Declaration of Helsinki and to the recommendations of the Ethics Committee at the Children's Hospital 'Bambino Gesù '. The nature and purpose of the study were carefully explained before informed consent was requested from each responsible guardian.
Definition of obesity, metabolic syndrome, insulin resistance and secretion Body mass index (BMI) (wt (kg)/ht 2 (m)) and Roher index (RI: wt (kg)/ht 3 (m)) were computed. 14 To compare BMI across different ages and between genders, BMI z-score was determined. 15 Identification of MS among children was based on the adult criteria defined by the National Cholesterol Education Program (NCEP). 1 In the adult definition, a minimum of three of the five major criteria (obesity determined by waist circumference, hypertension, low high-density lipoprotein (HDL) cholesterol levels, elevated triglycerides and glucose intolerance) should be fulfilled. These criteria have been modified for children. 16 Obesity was defined as a BMIX97th percentile adjusted for age and sex; overweight as a BMI within the 85th and the 96th percentiles; hypertriglyceridaemia as triglycerides 495th percentile for age, gender and race; 17 low HDL cholesterol as concentrations o5th percentile for age and sex; 17 elevated blood pressure as systolic or diastolic BP495th percentile for age and sex. 18 Glucose intolerance was defined according to the criteria of the American Diabetes Association. 19 Therefore, we defined MS in presence of X3 of the following 4 criteria: obesity, hypertension, dyslipidaemia (low HDL or elevated triglycerides) and glucose intolerance. 16 Insulin resistance was determined by the homeostatic model assessment (HOMA-IR ¼ (insulin Â glucose)/22.5); 20 insulin sensitivity by the quantitative insulin-sensitivity check index (QUICKI ¼ 1/(log plasma fasting insulin (mIU l À1 ) þ log plasma fasting glucose (mg dl À1 ))) 21 and the insulin sensitivity index (ISI composite ¼ (10 000/square root of (fasting glucose Â fasting insulin) Â (mean glucose Â mean insulin during oral glucose tolerance test (OGTT))).
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Insulin secretion was calculated as the corrected insulin response from 30 min insulin and glucose levels: (insulin 30/(glucose 30 Â (glucose 30-3.9))) (mIU Â mmol the Homa-b cell % ((fasting insulin Â 3.33)/(fasting glucoseÀ3.5)). 20 Estimation of body composition Total body fat (TBF) was estimated from total body dualenergy X-ray absorptiometry (DXA) scans made with a QDR-1500 total body scanner (Hologic Inc., Waltmann, MA, USA) in the pencil-beam mode with the enhanced whole body analysis (software version 5.67).
Biochemical assays
Serum was stored at À801C for later assays. Plasma glucose was measured in triplicate by the glucose oxidase technique on a Beckman glucose analyzer (Beckman, Fullerton, CA, USA) and plasma insulin by a specific radioimmunoassay (MYRIA Technogenetics, Milan, Italy). Serum triglycerides (intra-assay coefficient of variation (CV) 1.5% and interassay CV 1.8%), total (intra-assay CV 0.8%; inter-assay CV 1.7%) and HDL cholesterol (intra-assay CV 0.95%, interassay CV 1.3%) were measured by routine colorimetric assays (Roche/Hitachi Modular P/D, Can 433, Milan, Italy).
Liver histology
Biopsies were performed and processed as described elsewhere. 12 The main histological features described in NAFLD/ NASH including steatosis, inflammation (portal and lobular), hepatocyte ballooning and fibrosis were scored by using the Scoring System for NAFLD. 25 Steatosis was graded on a four- were combined in a score from 0 to 8, named NAFLD activity score (NAS). Cases with NASX5 are diagnostic of NASH, cases with NASp2 are diagnostic of simple steatosis, whereas cases in between are considered indeterminate. 25 Iron storage was scored from 0 to 4 according to Searle. 26 Statistical analysis Data are presented as mean7s.d. The Kolmogorov-Smirnov goodness-of-fit test was used for determining whether sample data are likely to derive from a normal-distributed population. RI, triglycerides, ALT, gGT, white blood cells, fasting insulin, mean values of insulin during the OGTT, HOMA-IR, insulin secretion and histological grades diverged significantly from normal distribution and were logarithmically transformed before analysis. The non-parametric Spearman correlation coefficient was used to assess significant correlations among variables. One-way analysis of variance followed by analysis of covariance using general linear models (to correct for effect modifiers, such as sex, age and BMI z-score) were used to determine differences in insulin resistance and secretion. Univariate analysis, KruskalWallis test and Bonferroni's post hoc test for multiple comparisons were carried out by standard techniques whenever appropriate. Level of significance was set at a ¼ 0.05. SPSS 11.5 for Windows (SPSS Inc., Chicago, IL, USA) was used. between sexes). Hypertension accounted for 40%, while prevalence of overt diabetes was 2%. According to the family history, obesity was diagnosed in 7% of both first-and second-degree relatives; type 2 diabetes mellitus in no relative of first degree and in 17% of second degree; dyslipidaemia in 47 and 41%, respectively; hypertension in 38% first degree and 40% second degree. Table 3 displays mean values of metabolic variables in subjects with no sign of MS, 1-2 factors associated with the syndrome and subjects with MS. Levels of ALT and aspartate aminotransferase (AST) increased as the number of comorbidities increased up to full MS (Pp0.05 for all comparison). Subjects with no sign, 1-2 factors associated with MS, and those with overt MS showed statistically different values of fasting and after OGTT insulin, HOMA-IR and ISI composite (Table 3 , analysis of variance), but no differences in NAS score. Fibrosis was present in 8% subjects with no MS; in 46% with 1-2 comorbidities and in 45% MS subjects (Pp0.01 Metabolic syndrome and paediatric NAFLD M Manco et al among subjects with no risk factor and the other two groups). A grade of steatosis X2 was present in 11, 51 and 38% subjects (P ¼ 0.05 among subjects with no risk factor and the other two groups). Necroinflammation was present in 11, 64 and 25%, respectively (P ¼ NS). Concerning histology concerns, steatosis was present in all subjects. It was mostly macrovescicular. Inflammation was present in 69% biopsies. Hepatocyte ballooning was found in 53% cases. PAS-D-positive cells containing phagocytosed cells debris were present in the portal tract and/or in the sinusoids. No Mallory's hyaline was noted in any case, and mild iron deposition was present in three cases. Diagnosis of NASH was formulated in 38 patients (NASX5), a diagnosis of simple steatosis (NASp2) was made in 41 patients; whereas 41 were considered indeterminate. When the criteria of Schwimmer et al. 27 were applied, only 3% patients met the criteria for NASH type 2 diagnosis, and 30% children encountered the criteria for NASH type 2. Most patients showed an overlapping of NASH types 1 and 2 (54%). Increased fibrosis was observed in 67% patients. Bioptic signs of cirrhosis were not detected in any patient. Noteworthy, 23% patients had normal values of ALT at the time of biopsy. They showed significantly lower fat mass (15.1177.23 vs 18.8174.64 kg; P ¼ 0.03) and triglycerides (83.89724.57 vs 113.54780.18; P ¼ 0.05) as compared with subjects with increased aminotransferases. When the population was stratified according to levels of ALT, either normal or increased, prevalence of steatosis was 86 vs 100% (Pp0.001), fibrosis 64 vs 67% (Pp0.001), necroinflammation 61 vs 74% (Pp0.001) and NAS score X55 vs 18% (P ¼ 0.04).
Results
Analysis of variance failed to find any significant difference among subjects when divided according to the NAS score (Table 4) . ; P ¼ 0.03) and HOMA-IR (3.0671.70 vs 2.6671.5; Pp0.001). Figure 1 shows the relation between ISI composite and IGI in patients with and without fibrosis. In Figure 2a , values of HOMA-IR and HOMA b-cell secretion are represented in both groups of subjects, while mean values of ISI composite and IGI are represented in Figure 2b .
Univariate analysis
Among histological features, namely steatosis, necroinflammation, either lobular or portal inflammation, ballooning and fibrosis, grade of fibrosis was the only one associated with MS (P ¼ 0.05).
Discussion
Diagnosis of MS is very common in children affected by fatty liver disease, being observed in more than 50% of them. Patients with MS show levels of aminotransferases significantly higher than children without MS. Fibrosis and severe steatosis are frequently reported. Among comorbidities, obesity, dyslipidaemia and hypertension are largely described in fatty liver disease, while insulin resistance and excessive body weight (either obesity or overweight) are almost universal findings. Nevertheless, 7% patients are normal weight children, even though insulin-resistant. Thus, therapeutic attempts based on the prescription of healthy diet and regular physical exercise should be encouraged in normal-weight patients too 12 with the purpose to reduce insulin resistance and hence fatty liver infiltration and inflammation. So far, large population-based studies have tried to establish the prevalence of the MS in the paediatric age by adapting the Adult Treatment Panel III criteria of the National Education Program. 16, 27 The syndrome occurs in 4.2% of healthy adolescents. 28 Its prevalence increases to 6.1 and 28.7% in overweight and obese adolescents, respectively, 27 and, according to this report, it achieves the rate of 66% in children with fatty liver disease. Our study represents the first survey looking at the prevalence of MS in one of the largest biopsy-proven series of NAFLD children. It may represent the extension of a previous study performed in 84 children with a different aim. In that study, we described lower rates of hypertension and dyslipidaemia, both defined by using fixed cutoffs, Metabolic syndrome and paediatric NAFLD M Manco et al which were independent of age and gender. 12 Furthermore, we did not evaluate b-cell function.
In cohorts of biopsy-proven NAFLD/NASH children from United States, Schwimmer et Lavine 13, 29 found obesity in 92% and overweight in 6% of patients. Type 2 diabetes mellitus was more frequently diagnosed as compared with our series, being described in 8% of population. On the contrary, prevalence of insulin resistance, defined either as HOMA-IRX2 or QUICKIp0.339, overlapped in both series. The authors did not provide data on insulin secretion and MS. Apart from differences in prevalence of comorbidities, it is also worth highlighting significant differences in histology with respect to the Schwimmer's series. 13, 29 These observations have been described elsewhere and discussed in detail. 12 Briefly, in the Rome cohort, type 1 NASH seems less frequent than in the SanDiego series; therefore, our patients having mostly type 2 NASH or a kind of portal injury that were classified them as overlapping types 1 and 2.
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A reasonable explanation for these divergences may be the large number (77%) of Hispanic and Asian patients in the SanDiego series compared with only Caucasians in our cohort.
As far as b-cell function is concerned, fasting insulin secretion (HOMA-b cell) is significantly increased in patients affected by severe steatosis and it trends to be in those with fibrosis ( Figure 2a) . Conversely, patients with liver fibrosis have significantly decreased insulinogenic index (Figure 2b) , which means likely an impairment of the first-phase insulin secretion. 28 They also show the left shift of the hyperbola (Figure 1 ), representing the relation between insulin action and secretion, the so-called 'disposition index'. 30 Accordingly, these children may be those who are probably at risk of developing the impairment of the glucose tolerance. Histological findings correlate significantly with clinical and biochemical factors. A grade of steatosis X2 is associated with higher BMI z-score, indexes of insulin resistance and b-cell function. Necroinflammation correlates with BMI z-score, RI, fasting glucose and total cholesterol, levels of aminotransferases and white blood cell count. Fibrosis is associated with higher body weight and BMI z-score, cholesterol and triglyceride levels, insulin resistance, fasting insulin and average values of the hormone during the OGTT. Noteworthy among histological features is that fibrosis is significantly associated with the MS.
Finally, it is remarkable that 23% of patients had normal values of ALT at the time of biopsy even though fibrosis was observed in 60% of them. This observation confirms that aminotransferases do not necessary reflect the grade in liver derangement 2 and suggests that NAFLD/NASH may be underdiagnosed and undertreated in children since in most studies and in clinical practice, ALT levels and liver brightness remain the main clinical criteria to diagnose the disease.
In conclusion, prevalence of either MS or clinical/ biochemical variables associated with its diagnosis is remarkable in children with biopsy-proven NAFLD/NASH. Presence of one or more comorbidities augments significantly the risk of fibrosis, which is consistent in case of full MS. For this reason, metabolic risk factors should be carefully evaluated and aggressively treated in these patients. Vice versa, in the presence of MS or its components, NAFLD/NASH should be investigated by repeated measurement of liver enzymes and liver ultrasounds. Further studies are warranted to evaluate the role and timing of liver biopsy.
